Search
Searching Content indexed under Intellectual Property by Muriel Liberto ordered by Published Date Descending.
Links to Result pages
 
1  
 
Title
Country
Organisation
Author
Date
1
With Its Vanda Pharma And Berkheimer Memos, USPTO Provides Increased Clarity And Predictability In The Patent Eligibility Determination In A Further Boost For Stakeholders And Innovators In Personalized Medicine
In the time since the Federal Circuit issued its Vanda Pharma decision in April, Vanda Pharm. Inc. v West-Ward Pharm. Intl. Ltd. 887 F.3d 1117 (Fed. Cir. 2018) ...
United States
25 Jul 2018
2
With Its Vanda Pharma And Berkheimer Memos USPTO Provides Increased Clarity, Predictability For Patent Eligibility In A Further Boost For Inventions In Personalized Medicine
The recent Vanda Pharma memo goes even further toward easing the path to patent eligibility by acknowledging that methods of treating are eligible under the first step of the Mayo inquiry.
United States
29 Jun 2018
3
Personalized Medicine Gets A Boost From Federal Circuit's Vanda Pharma Decision – PART II: Enforcement
In the real world, at least the steps of "assaying" and "administering" are seldom performed by a single actor, and if they are, that actor is most likely to be a doctor.
United States
1 May 2018
4
Personalized Medicine Gets A Boost From Federal Circuit's Vanda Pharma Decision
The Federal Circuit provided a welcome boost for stakeholders in the field of personalized medicine with its recent decision in Vanda Pharm. Inc. v West-Ward Pharm. Intl. Ltd. (2016-2702, 2016-2708 April 13, 2018).
United States
23 Apr 2018
5
USPTO Guidance For Examiners Takes Expansive View Of Myriad And Prometheus Decisions
The USPTO issued a memorandum with guidance for determining the patent eligibility of claims relating to products of nature and laws of nature.
United States
11 Mar 2014
6
Leahy-Smith America Invents Act – What You Need to Know Now
Far-ranging changes to the U.S. patent system will begin to take effect with President Obama’s signing of the Leahy-Smith America Invents Act ("the Leahy-Smith AIA").
United States
22 Sep 2011
7
Myriad Impact Of The Federal Circuit’s Decision In Myriad Genetics
On July 29, 2011, a split panel of the U.S. Court of Appeals for the Federal Circuit confirmed the patentability of "isolated" DNA molecules, to the relief of many in the biotechnology community. Association for Molecular Pathology v. U.S. Patent and Trademark Office (Fed. Cir. 2011).
United States
15 Aug 2011
Links to Result pages
 
1